Ertapenem Does NOT Cover Campylobacter
Ertapenem lacks clinically reliable activity against Campylobacter species and should not be used for suspected or confirmed Campylobacter infections. While emerging research shows some Campylobacter strains developing carbapenem resistance genes, this reflects horizontal gene transfer rather than therapeutic susceptibility—ertapenem remains ineffective for treating campylobacteriosis.
Microbiologic Evidence
The FDA drug label for ertapenem explicitly lists its spectrum of activity, and Campylobacter is notably absent from both the approved indications and the list of organisms with established clinical efficacy 1. The label details activity against Enterobacteriaceae, anaerobes, and select Gram-positive organisms, but makes no mention of Campylobacter coverage.
Research confirms ertapenem's spectrum excludes Campylobacter:
- Ertapenem demonstrates activity against Enterobacteriaceae, Streptococcus pneumoniae, and anaerobes, but has "restricted activity against nosocomial pathogens" and lacks coverage of atypical enteric pathogens 2, 3
- The drug's spectrum is narrower than other carbapenems, specifically lacking reliable activity against Pseudomonas, Enterococcus, and notably Campylobacter 4, 5
Clinical Resistance Data
Recent surveillance data paradoxically shows Campylobacter developing carbapenem resistance:
- 60.71% of C. coli isolates showed meropenem resistance and 35.71% showed ertapenem resistance in avian samples 6
- Carbapenemase genes (NDM, OXA-48, VIM) have been detected in Campylobacter isolates 7, 8
- Clinical cases document MICs >32 mg/L for both ertapenem and meropenem in C. jejuni 8
Critical caveat: This resistance reflects gene acquisition making already-resistant organisms more resistant—it does NOT indicate ertapenem ever had therapeutic activity against Campylobacter. The baseline MICs are far above achievable serum concentrations.
Appropriate Treatment for Campylobacter
For Campylobacter gastroenteritis requiring treatment:
- First-line: Azithromycin or erythromycin (100% susceptibility maintained in recent Australian surveillance) 9
- Alternative: Fluoroquinolones (though 22% ciprofloxacin resistance now documented in some regions) 9
- Severe cases: Combination therapy with macrolides plus aminoglycosides may be considered
Guidelines for intra-abdominal infections, skin/soft tissue infections, and community-acquired pneumonia recommend ertapenem for polymicrobial infections involving Enterobacteriaceae and anaerobes 10, 11, but these recommendations assume typical enteric flora—not Campylobacter-specific coverage.
Key Clinical Pitfall
Do not assume carbapenem coverage extends to all enteric pathogens. Ertapenem's Group 1 carbapenem classification means it lacks the anti-pseudomonal and broader Gram-negative activity of imipenem/meropenem, and it has never demonstrated activity against Campylobacter species despite being used for other gastrointestinal infections 12.